MD Anderson’s patient-centric approach to research is advancing the understanding of malignant and non-malignant blood disorders and extending patients’ lives.
At the ASH Annual Meeting and Exposition, our experts showcased their practice-changing work with colleagues from across the globe for large-scale discussion.
Below is a snapshot of the work our experts presented at the 2019 meeting, as well as more about our pioneering hematology research. Bookmark this page for updates about next year’s meeting and beyond.
of chemotherapy and blinatumomab improves survival for patients
with B-cell acute lymphoblastic leukemia
A study shows first-line treatment with chemotherapy plus a monoclonal antibody improves survival in newly diagnosed patients with Philadelphia chromosome-negative B-cell ALL.
A study finds that axi-cel is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma
antibody-drug conjugate shows promising early results in rare
Early study data shows 29% overall response rate, favorable safety profile in blastic plasmacytoid dendritic cell neoplasm
MD Anderson News
Conferences and Educational Events
View a list of professional, CME-accredited conferences and educational events.
Moon Shots Program
Our intentions are noble – put blood cancers at the forefront of our investigation to make their cure a future reality. Our process is groundbreaking – use in-house, industry-quality platforms to ensure that our breakthrough discoveries aren’t left sitting in research labs.
By combining Innovation, Collaboration and Scale, the Moon Shots Program® is revolutionizing the conventional medical research approach to rapidly adapt pre-clinical findings into treatment options for challenging blood cancers.